| Epigenetics in human disease and prospects for epigenetic therapy G Egger, G Liang, A Aparicio, PA Jones Nature 429 (6990), 457-463, 2004 | 4345 | 2004 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 487 | 2021 |
| Platinum-based chemotherapy for variant castrate-resistant prostate cancer AM Aparicio, AL Harzstark, PG Corn, S Wen, JC Araujo, SM Tu, ... Clinical cancer research 19 (13), 3621-3630, 2013 | 459 | 2013 |
| Aggressive variants of castration-resistant prostate cancer H Beltran, S Tomlins, A Aparicio, V Arora, D Rickman, G Ayala, J Huang, ... Clinical Cancer Research 20 (11), 2846-2850, 2014 | 448 | 2014 |
| Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy S Jiao, SK Subudhi, A Aparicio, Z Ge, B Guan, Y Miura, P Sharma Cell 179 (5), 1177-1190. e13, 2019 | 321 | 2019 |
| Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer L Li, S Karanika, G Yang, J Wang, S Park, BM Broom, GC Manyam, W Wu, ... Science signaling 10 (480), eaam7479, 2017 | 282 | 2017 |
| Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer E Efstathiou, M Titus, S Wen, A Hoang, M Karlou, R Ashe, SM Tu, ... European urology 67 (1), 53-60, 2015 | 279 | 2015 |
| Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers AM Aparicio, L Shen, ELN Tapia, JF Lu, HC Chen, J Zhang, G Wu, ... Clinical cancer research 22 (6), 1520-1530, 2016 | 251 | 2016 |
| A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study TH Luu, RJ Morgan, L Leong, D Lim, M McNamara, J Portnow, P Frankel, ... Clinical Cancer Research 14 (21), 7138-7142, 2008 | 250 | 2008 |
| Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities SK Subudhi, A Aparicio, J Gao, AJ Zurita, JC Araujo, CJ Logothetis, ... Proceedings of the National Academy of Sciences 113 (42), 11919-11924, 2016 | 220 | 2016 |
| Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma E Jonasch, CG Wood, SF Matin, SM Tu, LC Pagliaro, PG Corn, A Aparicio, ... Journal of clinical oncology 27 (25), 4076-4081, 2009 | 217 | 2009 |
| Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy S Goswami, I Apostolou, J Zhang, J Skepner, S Anandhan, X Zhang, ... The Journal of clinical investigation 128 (9), 3813-3818, 2018 | 191 | 2018 |
| A phase 2 trial of sunitinib in patients with advanced non–clear cell renal cell carcinoma NM Tannir, E Plimack, C Ng, P Tamboli, NB Bekele, L Xiao, L Smith, Z Lim, ... European urology 62 (6), 1013-1019, 2012 | 176 | 2012 |
| Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer CJ Logothetis, GE Gallick, SN Maity, J Kim, A Aparicio, E Efstathiou, ... Cancer discovery 3 (8), 849-861, 2013 | 165 | 2013 |
| Modeling a lethal prostate cancer variant with small-cell carcinoma features V Tzelepi, J Zhang, JF Lu, B Kleb, G Wu, X Wan, A Hoang, E Efstathiou, ... Clinical cancer research 18 (3), 666-677, 2012 | 165 | 2012 |
| Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial PG Corn, EI Heath, A Zurita, N Ramesh, L Xiao, E Sei, E Li-Ning-Tapia, ... The lancet oncology 20 (10), 1432-1443, 2019 | 163 | 2019 |
| Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low‐dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis E Jonasch, P Corn, LC Pagliaro, CL Warneke, MM Johnson, P Tamboli, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 136 | 2010 |
| Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer SK Subudhi, L Vence, H Zhao, J Blando, SS Yadav, Q Xiong, A Reuben, ... Science translational medicine 12 (537), eaaz3577, 2020 | 135 | 2020 |
| Understanding the lethal variant of prostate cancer: power of examining extremes A Aparicio, CJ Logothetis, SN Maity Cancer discovery 1 (6), 466-468, 2011 | 132 | 2011 |
| TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate CC Guo, JY Dancer, Y Wang, A Aparicio, NM Navone, P Troncoso, ... Human pathology 42 (1), 11-17, 2011 | 114 | 2011 |
